Editor's Note Preliminary research shows removing breasts or ovaries can significantly improve survival and reduce recurrence risk in young breast cancer patients with BRCA mutations, HealthDay reported December 13. The findings were presented this week at the San Antonio Breast Cancer Symposium. According to the article, researchers analyzed data from…
Editor's Note Active monitoring for certain breast cancer patients offers similar outcomes to surgery with fewer side effects, according to research detailed in a December 16 article from Oncology News Central. Presented at the 2024 San Antonio Breast Cancer Symposium and published in JAMA, The COMET trial supports the safety…
Editor's Note Perioperative immunotherapy is reshaping treatment strategies for early-stage non-small cell lung cancer (NSCLC) without actionable mutations, according to Dr. Roy S. Herbst of Yale Cancer Center. In a recent interview with OncLive, the oncology expert highlighted the promise of neoadjuvant and adjuvant therapies to improve outcomes for these…
Editor's Note A scoping review of 15 studies reveals that the COVID-19 pandemic significantly disrupted oncological abdominal surgery (OAS), leading to postponed or canceled procedures, adoption of alternative treatment plans, and increased psychological stress among surgical teams. Published November 5 in the American Journal of Surgery, the findings emphasize the…
Editor's Note In a recent study, lung cancer patients using wearable devices showed significantly improved postoperative physical activity and pulmonary function as well as reduced symptoms such as dyspnea and pain. Published September 20 in Jama Network Open, the study compared 74 patients in the intervention group (who used wearable…
Editor's Note An algorithm developed by researchers at Duke University Medical Centre is designed to assist patients diagnosed with intermediate-stage liver cancer in making decisions about surgery, according to an October 9 report in News Medical Life Sciences. Known as the Modified Metroticket, this tool predicts overall survival and recurrence-free…
Editor's Note The US Food & Drug Administration (FDA) has approved immunotherapy durvalumab for perioperative treatment of resectable non-small cell lung cancer (NSCLC), according to an August 15 announcement. The approval is for durvalumab (Imfinzi, AstraZeneca) in combination with platinum-based chemotherapy as a neoadjuvant treatment, followed by durvalumab alone as…
Editor's Note A post hoc analysis of the SCOT phase 3 randomized clinical trial reveals that initiating adjuvant chemotherapy more than 6 weeks after surgery is linked to worse disease-free survival (DFS) in patients with high-risk stage II and stage III colorectal cancer. Published June 12 in JAMA Surgery, the…
Editor's Note Medical professionals have long accepted that bilateral mastectomy does not improve survival outcomes for breast cancer patients. However, a study published in JAMA Oncology reveals a puzzling finding: Those who develop a second cancer in the other breast have a higher risk of death. As detailed in a…
Editor's Note A Massachusetts man, Marty Kedian, regained his voice after a pioneering larynx transplant at the Mayo Clinic in Arizona, The Associated Press (AP) reported July 9. According to the article, Kedian is only the third person in the U.S. to receive a total larynx transplant and the first…